Genzyme General Newswire (Page 2)

Genzyme General Newswire (Page 2)

Comprehensive Real-Time News Feed for Genzyme General. (Page 2)

Results 21 - 40 of 633 in Genzyme General

  1. Akebia Appoints To Its Board Of DirectorsRead the original story

    Tuesday Aug 2 | BioSpace

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced that Scott A. Canute, former President of Global Manufacturing and Corporate Operations of Genzyme Corporation, has been appointed to Akebia's Board of Directors.

    Comment?

  2. Sanofi (SNY) Downgraded by Zacks Investment Research to "Sell"Read the original story w/Photo

    Wednesday Aug 3 | AmericanBankingNews.com

    According to Zacks, "Although Sanofi posted in-line earnings in Q2, both earnings & revenues were down y/y. The Diabetes franchise is under significant pressure with key product, Lantus, facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets & Japan.

    Comment?

  3. Akebia Therapeutics Appoints Scott A. Canute to its Board of DirectorsRead the original story w/Photo

    Tuesday Aug 2 | Freshnews

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced that Scott A. Canute, former President of Global Manufacturing and Corporate Operations of Genzyme Corporation, has been appointed to Akebia's Board of Directors. "Scott brings more than three decades of experience managing global manufacturing and operations to Akebia," said Muneer A. Satter, Chairman of Akebia's Board of Directors.

    Comment?

  4. Analysts Set Sanofi (NYSE:SNY) Price Target at $51.50Read the original story w/Photo

    Saturday Jul 30 | Daily Political

    Shares of Sanofi have been given a consensus rating of "Hold" by the fifteen ratings firms that are currently covering the firm. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the company.

    Comment?

  5. Sanofi profits down despite growth at Genzyme unitRead the original story

    Friday Jul 29 | KDWN

    Drugmaker Sanofi has reported an 11 percent fall in profit in the second quarter despite double-digit growth of its biotech unit Genzyme. The Paris-based company reported Friday a fall in net income of 11 percent to 1.16 billion euros and a 5 percent drop in net revenue to 8.14 billion euros.

    Comment?

  6. Sanofi net falls by 11pc to 1.1b eurosRead the original story

    Friday Jul 29 | The Standard

    Drugmaker Sanofi has reported an 11 percent fall in profit in the second quarter despite double-digit growth of its biotech unit Genzyme. The Paris-based company reported a fall in net income of 11 percent to 1.16 billion euros and a 5 percent drop in net revenue to 8.14 billion euros.

    Comment?

  7. Sanofi (SNY) Rating Increased to Buy at TheStreetRead the original story w/Photo

    Friday Jul 29 | Daily Political

    Several large investors have recently modified their holdings of the stock. Rehmann Capital Advisory Group increased its stake in shares of Sanofi by 0.5% in the second quarter.

    Comment?

  8. Sanofi sales and profit slide on U.S. pricing, VenezuelaRead the original story w/Photo

    Friday Jul 29 | Reuters

    A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. French drugmaker Sanofi's sales and profit fell in the second quarter despite double-digit growth at biotech arm Genzyme, as the diabetes division came under sustained pricing pressure in the United States.

    Comment?

  9. French and Benelux stocks-Factors to watch on July 29Read the original story

    Thursday Jul 28 | Reuters

    Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks. Britain's government has said it will launch a new review into a controversial project to build two new nuclear reactors led by French utility EDF EDF.PA, the country's first new nuclear plant in decades.

    Comment?

  10. Sanofi Profit Down as Diabetes Drug Sales SlipRead the original story w/Photo

    Thursday Jul 28 | Wall Street Journal

    French drugmaker Sanofi SA on Friday reported a fall in second-quarter net profit, hurt by dwindling diabetes U.S. sales and adverse currency moves but said it still expected to meet its profit target this year.

    Comment?

  11. Sanofi (SNY) Upgraded at TheStreetRead the original story w/Photo

    Thursday Jul 28 | AmericanBankingNews.com

    Shares of Sanofi traded up 0.40% during trading on Wednesday, hitting $42.60. The stock had a trading volume of 1,003,077 shares.

    Comment?

  12. Sanofi (SNY) Lifted to Buy at TheStreetRead the original story w/Photo

    Thursday Jul 28 | AmericanBankingNews.com

    Sanofi traded up 0.40% during mid-day trading on Wednesday, hitting $42.60. The company's stock had a trading volume of 1,003,077 shares.

    Comment?

  13. ARIAD Pharmaceuticals' (ARIA) CEO Paris Panayiotopoulos on Q2 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Thursday Jul 28 | Seeking Alpha

    Thank you for holding for ARIAD Pharmaceuticals Second Quarter 2016 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  14. Sanofi Receives FDA Approval of Adlyxin (lixisenatide) for Treatment of Adults With Type 2 DiabetesRead the original story w/Photo

    Tuesday Jul 26 | Drugs.com

    Sanofi announced today that the U.S. Food and Drug Administration approved Adlyxin , a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. "The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose targets," said Peter Guenter, Executive Vice President, Head, Global Diabetes & Cardiovascular Business Unit, Sanofi.

    Comment?

  15. Court Report - July 2016 #2Read the original story w/Photo

    Wednesday Jul 27 | JD Supra

    Genzyme Corp. et al. v. Zydus Pharmaceuticals Inc. 1:16-cv-00540; filed June 29, 2016 in the District Court of Delaware Infringement of U.S. Patent Nos.

    Comment?

  16. Sanofi (SNY) Position Cut by Royal Bank of CanadaRead the original story w/Photo

    Wednesday Jul 27 | Daily Political

    Royal Bank of Canada decreased its position in Sanofi by 0.7% during the first quarter, Holdings Channel reports. The firm owned 2,030,328 shares of the company's stock after selling 15,284 shares during the period.

    Comment?

  17. Sanofi (SNY) Rating Increased to Hold at Zacks Investment ResearchRead the original story w/Photo

    Wednesday Jul 27 | Daily Political

    According to Zacks, "Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology, and CNS disorders, among others. New products like Toujeo, Aubagio and Lemtrada should do well.

    Comment?

  18. Sanofi (NYSE:SNY) Receives Average Recommendation of "Hold" from BrokeragesRead the original story w/Photo

    Jul 25, 2016 | AmericanBankingNews.com

    Sanofi has received an average recommendation of "Hold" from the fifteen brokerages that are currently covering the company. Three analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating on the company.

    Comment?

  19. Sanofi (SNY) Raised to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Jul 25, 2016 | AmericanBankingNews.com

    According to Zacks, "Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology, and CNS disorders, among others. New products like Toujeo, Aubagio and Lemtrada should do well.

    Comment?

  20. Global Clinical Laboratory Services Market is Expected to Grow USD...Read the original story

    Jul 24, 2016 | PR.com

    Credenceresearch.com has announced the addition of "Global Clinical Laboratory Services Market Is Expected To Grow USD 248.5 Bn By 2022: Credence Research" Market Research Report to their Database. San Jose, CA, July 24, 2016 -- -- The latest market report published by Credence Research, Inc. "Global Clinical Laboratory Services Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022," the clinical laboratory services market was valued at USD 165.8 Bn in 2015, and is expected to reach USD 248.5 Mn by 2022, expanding at a CAGR of 5.9% from 2016 to 2022.

    Comment?